Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Trial of AC-701 for Treatment of Skin Rash in Subjects With EGFR Inhibitor Therapy

NCT04239846 is registered in ClinicalTrials.gov with TWi Biotechnology, Inc. as lead sponsor.

NCT NCT04239846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04239846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Trial of AC-701 for Treatment of Skin Rash in Subjects With EGFR Inhibitor Therapy
Lead sponsor
TWi Biotechnology, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 2, 2019
Completion date
May 26, 2021
Enrollment
74 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

egfr inhibitor-induced skin rash